Objectives Possible Generics in 2013
... Efficacy at 1 year in 2 large studies: Mean weight loss 8.6-10.9% of body weight (~10 kg) 5% or greater loss: 67-70% of patients 10% or greater loss: 48-54% 48 54% of patients ...
... Efficacy at 1 year in 2 large studies: Mean weight loss 8.6-10.9% of body weight (~10 kg) 5% or greater loss: 67-70% of patients 10% or greater loss: 48-54% 48 54% of patients ...
Rivaroxaban prescribing guidance 2016
... Note: Rivaroxaban is also licensed, at a higher dose for stroke prevention in non-valvular atrial fibrillation, treatment and secondary prevention of venous thromboembolism. Guidance for use for these indications can be found at: www.swlmcg.nhs.uk ...
... Note: Rivaroxaban is also licensed, at a higher dose for stroke prevention in non-valvular atrial fibrillation, treatment and secondary prevention of venous thromboembolism. Guidance for use for these indications can be found at: www.swlmcg.nhs.uk ...
Major Bleeding and Hemorrhagic Stroke With Direct Oral
... resolved by consensus. The degree of RF was defined in accordance with the criteria used by the included trials, based on the following grouping: eCrCL < 50 mL/min and eCrCL 50 to 80 mL/min. Although patients with eCrCL < 30 or 25 mL/min were formally excluded from these trials, a few of these trials ...
... resolved by consensus. The degree of RF was defined in accordance with the criteria used by the included trials, based on the following grouping: eCrCL < 50 mL/min and eCrCL 50 to 80 mL/min. Although patients with eCrCL < 30 or 25 mL/min were formally excluded from these trials, a few of these trials ...
Plasma Protein Binding
... Intravenous (정맥), intraperitoneal (복강), intramuscular (근육), subcutaneous (피하), transdermal (피부) ...
... Intravenous (정맥), intraperitoneal (복강), intramuscular (근육), subcutaneous (피하), transdermal (피부) ...
click here to the doc
... (extent of absorption). However, food does not affect the plasma LDL-C lowering efficacy of Atosta. Evening Atosta dose administration is known to reduce the Cmax (rate of absorption) and AUC (extent of absorption) by 30% each. However, time of administration does not affect the plasma LDL-C loweri ...
... (extent of absorption). However, food does not affect the plasma LDL-C lowering efficacy of Atosta. Evening Atosta dose administration is known to reduce the Cmax (rate of absorption) and AUC (extent of absorption) by 30% each. However, time of administration does not affect the plasma LDL-C loweri ...
Print This Information
... Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed. Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, upto-date, a ...
... Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed. Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, upto-date, a ...
INHIBITOR of BACTERIAL PROTEIN SYNTHESIS
... • highly polar compounds • not abosorbed after oral administration (only parenteral dosage forms im, iv) • After paranteral administration they are absorbed well • limited tissue penetration (can’t cross BBB, can’t enter the eye) • GF is the major mode of excretion (attention in renal insufiency) • ...
... • highly polar compounds • not abosorbed after oral administration (only parenteral dosage forms im, iv) • After paranteral administration they are absorbed well • limited tissue penetration (can’t cross BBB, can’t enter the eye) • GF is the major mode of excretion (attention in renal insufiency) • ...
Heart Failure:
... Nearly all residents will face side effects from carbidopa/levodopa including drug induced psychosis and hallucinations. It is typically not possible to lower the dose to reduce these symptoms and psychoactive therapy often is necessary. The two classes of psychoactive drugs shown to have the most b ...
... Nearly all residents will face side effects from carbidopa/levodopa including drug induced psychosis and hallucinations. It is typically not possible to lower the dose to reduce these symptoms and psychoactive therapy often is necessary. The two classes of psychoactive drugs shown to have the most b ...
Heparin, low-molecular–weight heparins, and heparin - hem
... are available for clinical use worldwide. Because of manufacturing differences, each of the LMWHs exhibit distinct pharmacologic and biochemical profiles [5]. The specific activity of these agents in the anticoagulant assays ranges from 35 to 45 anti-IIa U/mg, whereas the specific activity in terms ...
... are available for clinical use worldwide. Because of manufacturing differences, each of the LMWHs exhibit distinct pharmacologic and biochemical profiles [5]. The specific activity of these agents in the anticoagulant assays ranges from 35 to 45 anti-IIa U/mg, whereas the specific activity in terms ...
Stroke prevention and risk management for patients with non
... Dabigatran 150mg BD is superior to warfarin in preventing stroke and has a reduced risk of intracerebral hemorrhage. Total major bleeding is higher than warfarin (mostly GI bleeds) Dabigatran 110mg BD is non-inferior to warfarin in preventing stroke and has a reduced risk of bleeding, especially ...
... Dabigatran 150mg BD is superior to warfarin in preventing stroke and has a reduced risk of intracerebral hemorrhage. Total major bleeding is higher than warfarin (mostly GI bleeds) Dabigatran 110mg BD is non-inferior to warfarin in preventing stroke and has a reduced risk of bleeding, especially ...
A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes
... Who is included in the Analysis: The ITT analysis includes all patients randomized to a therapy irrespective of protocol deviations, discontinuation of study drug, drug administration errors, cross-over to another strategy, or withdrawal from the study by the subject. How long were they followed ...
... Who is included in the Analysis: The ITT analysis includes all patients randomized to a therapy irrespective of protocol deviations, discontinuation of study drug, drug administration errors, cross-over to another strategy, or withdrawal from the study by the subject. How long were they followed ...
Herbal Remedies and Drug Interactions
... man who took 40mg of Gingko extract twice a day along with 325 mg of Aspirin daily for one week. Also bilateral subdural hematomas in a 33 year old woman who took 60 mg of Gingko twice a day for two years. ...
... man who took 40mg of Gingko extract twice a day along with 325 mg of Aspirin daily for one week. Also bilateral subdural hematomas in a 33 year old woman who took 60 mg of Gingko twice a day for two years. ...
New Product Focus - SA Pharmaceutical Journal
... Patients need to take supplemental calcium and vitamin D during therapy with ibandronate.1 Ibandronate 3 mg/3 ml intravenously is administered every three months. If a dose is missed, the injection should be administered as soon as it is convenient.1 ...
... Patients need to take supplemental calcium and vitamin D during therapy with ibandronate.1 Ibandronate 3 mg/3 ml intravenously is administered every three months. If a dose is missed, the injection should be administered as soon as it is convenient.1 ...
managing atrial fibrillation - Heart and Stroke Foundation
... Clinical Criteria 1) Failed warfarin trial > 2 months > 35% INRs outside therapeutic range ...
... Clinical Criteria 1) Failed warfarin trial > 2 months > 35% INRs outside therapeutic range ...
Guidelines for the use of dabigatran and rivaroxaban
... • Rivaroxaban and apixaban should be used with caution in patients with CrCl 15 - 29 ml/min and are not suitable for patients with a CrCl <15 ml/min • The best method for reversing the NOACs is not known. Studies in human volunteers have shown that Prothrombin Complex Concentrate (PCC) can reverse t ...
... • Rivaroxaban and apixaban should be used with caution in patients with CrCl 15 - 29 ml/min and are not suitable for patients with a CrCl <15 ml/min • The best method for reversing the NOACs is not known. Studies in human volunteers have shown that Prothrombin Complex Concentrate (PCC) can reverse t ...
Implementation of NICE TAs 249, 256 and 275 Dabigatran
... • Rivaroxaban and apixaban should be used with caution in patients with CrCl 15 - 29 ml/min and are not suitable for patients with a CrCl <15 ml/min • The best method for reversing the NOACs is not known. Studies in human volunteers have shown that Prothrombin Complex Concentrate (PCC) can reverse t ...
... • Rivaroxaban and apixaban should be used with caution in patients with CrCl 15 - 29 ml/min and are not suitable for patients with a CrCl <15 ml/min • The best method for reversing the NOACs is not known. Studies in human volunteers have shown that Prothrombin Complex Concentrate (PCC) can reverse t ...
Updated Guidelines on Outpatient Anticoagulation
... (LMWH) are commonly used for the prevention and treatment of disorders such as systemic embolism associated with atrial fibrillation, stroke, and venous thromboembolism (VTE). LMWH allows for the initiation of anticoagulation therapy ...
... (LMWH) are commonly used for the prevention and treatment of disorders such as systemic embolism associated with atrial fibrillation, stroke, and venous thromboembolism (VTE). LMWH allows for the initiation of anticoagulation therapy ...
Tamoxifen
... of various drugs, including erythromycin, calcium channel blockers, and cyclosporine. ...
... of various drugs, including erythromycin, calcium channel blockers, and cyclosporine. ...
File
... Ibuprofen (Motrin) and another propionic acid derivative, ketoprofen (Orudis), are similar to aspirin in action, adverse effects, interactions, and contraindications. In addition to assessing for GI bleeding, renal function must be monitored with long-term therapy. Many patients who are allergic to ...
... Ibuprofen (Motrin) and another propionic acid derivative, ketoprofen (Orudis), are similar to aspirin in action, adverse effects, interactions, and contraindications. In addition to assessing for GI bleeding, renal function must be monitored with long-term therapy. Many patients who are allergic to ...
PowerPoint Presentation - LECTURE 10
... Circulatory Disorders Heparin • A natural substance in the liver that prevents clot formation. • Primary use is to prevent venous thrombosis that can lead to pulmonary embolism (PE) or stroke • Combines w/ antithrombin III inactivates thrombin and other clotting factors then the conversion of fib ...
... Circulatory Disorders Heparin • A natural substance in the liver that prevents clot formation. • Primary use is to prevent venous thrombosis that can lead to pulmonary embolism (PE) or stroke • Combines w/ antithrombin III inactivates thrombin and other clotting factors then the conversion of fib ...
ENZYMES
... Drugs may also act as false substrates, where the drug molecule undergoes chemical transformation to form an abnormal product that subverts the normal metabolic pathway. An example is the anticancer drug fluorouracil, which replaces uracil as an intermediate in purine biosynthesis but cannot be con ...
... Drugs may also act as false substrates, where the drug molecule undergoes chemical transformation to form an abnormal product that subverts the normal metabolic pathway. An example is the anticancer drug fluorouracil, which replaces uracil as an intermediate in purine biosynthesis but cannot be con ...
Using the BNF
... metabolism occur • Impaired drug metabolism –Rifampicin, Fusidic acid • Hypoproteinaemia (Hypoalbuminaemia is associated with reduced protein binding and increased toxicity of highly protein bound drugs) – Phenytoin, prednisolone • Reduced clotting –Warfarin & phenindione • Hepatic encephalopathy –s ...
... metabolism occur • Impaired drug metabolism –Rifampicin, Fusidic acid • Hypoproteinaemia (Hypoalbuminaemia is associated with reduced protein binding and increased toxicity of highly protein bound drugs) – Phenytoin, prednisolone • Reduced clotting –Warfarin & phenindione • Hepatic encephalopathy –s ...
Discovery and development of direct thrombin inhibitors
Direct thrombin inhibitors (DTIs) are a class of anticoagulant drugs that can be used to prevent and treat embolisms and blood clots caused by various diseases. They inhibit thrombin, a serine protease which affects the coagulation cascade in many ways. DTIs have undergone rapid development since the 90's. With technological advances in genetic engineering the production of recombinant hirudin was made possible which opened the door to this new group of drugs. Before the use of DTIs the therapy and prophylaxis for anticoagulation had stayed the same for over 50 years with the use of heparin derivatives and warfarin which have some well known disadvantages. DTIs are still under development, but the research focus has shifted towards factor Xa inhibitors, or even dual thrombin and fXa inhibitors that have a broader mechanism of action by both inhibiting factor IIa (thrombin) and Xa. A recent review of patents and literature on thrombin inhibitors has demonstrated that the development of allosteric and multi-mechanism inhibitors might lead the way to a more safer anticoagulant.